Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke

Sponsor
Xuanwu Hospital, Beijing
Study ID
NCT06134635
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Statins — DRUG
    Atorvastatin 20mg qn or rosuvastatin 10mg qn or pivastatin 2mg qn, oral
  • Evolocumab — DRUG
    Evolocumab 140mg twice a month, subcutaneous injection

Study Details

This is a prospective cohort study to investigate the early impact of evolocumab on patients with acute ischemic stroke (AIS) in China. Evolocumab, a proprotein convertase subtilisin/kexin taye 9 inhibitor, can significantly reduce low density lipoprotein cholesterol (LDL-C) levels and has a positive effect on improving cardiovascular events. However, existing studies have focused almost exclusively on the long-term effects of Evolocumab, and the early effects of Evolocumab on AIS patients remains unclear.

Key Dates

Start date
Dec 1, 2023
Status verified
Oct 2023
Primary completion
Nov 1, 2024
Completion
Dec 1, 2024

Study Design

Enrollment
80 participants (estimated)

Arms

  • Arm: Statin-alone group
    The participants in statin-alone group receive statins alone for lipid reduction.
  • Arm: PCSK9-i group
    The participants in PCSK9-i group receive statins and evolocumab for lipid reduction.

Primary Outcome Measure

LDL-C target achievement rate on Day 5, Month 3 [ Time Frame: Day 5, Month 3 ]

Central Contacts

Related Studies